metodologia.eyebrow
Formulation Methodology
The phrase references a specific analytical tradition. This page documents what it means in practice.
Denmark is home to Novo Nordisk — the company that invented and industrialized injectable GLP-1 peptide formulation, producing liraglutide (2009) and semaglutide (2017), and that today holds roughly half the global insulin market. Their analytical benchmark — HPLC-UV purity, ESI-MS identity confirmation, LAL endotoxin testing — is the standard against which injectable peptide quality is measured worldwide.
Denmark operates under the European Pharmacopoeia (Ph. Eur.), which mandates specific methods for peptide purity characterization. The methods Alpha Nordisk applies to every production lot are these same methods: reversed-phase C18 HPLC at 220 nm, ESI-MS mass confirmation, LAL gel-clot endotoxin testing, and Karl Fischer water determination. 'Danish Formulation Technology' describes a commitment to this analytical standard — the methodology of a tradition, not a geographic claim about manufacturing location.
Alpha Nordisk is not affiliated with Novo Nordisk A/S.
| Test | Method | Standard | Confirmation |
|---|---|---|---|
| Purity | HPLC-UV, C18 RP, 220 nm | Ph. Eur. 2.2.29 | Main chain ≥ 99.0% |
| Identity | ESI-MS, ≤5 ppm mass accuracy | Ph. Eur. 2.2.43 | Molecular formula confirmed |
| Endotoxin | LAL gel-clot assay | Ph. Eur. 2.6.14 | < 1.0 EU/mg |
| Water content | Karl Fischer titration | Ph. Eur. 2.5.12 | < 8.0% |
| Counterion | Ion chromatography | Internal SOP | Acetate (TFA-free) |
| Lot traceability | Accession registry | Internal | Each lot independently verifiable |
Ph. Eur. chapter references are published European Pharmacopoeia monograph numbers, verifiable in the Council of Europe pharmacopoeial compendium.
Why 220 nm
Peptide bond UV absorption at 220 nm is the universal analytical wavelength for unmodified peptide backbone detection. Reversed-phase C18 HPLC with UV detection at this wavelength resolves the main chain from truncation sequences, oxidation products, and aggregates — impurities that co-elute or are invisible at other wavelengths. It is the method Ph. Eur. 2.2.29 mandates for small-molecule and peptide liquid chromatography, and the wavelength applied to semaglutide intermediate purity assessment in Novo Nordisk's published quality documentation. A purity claim without specifying wavelength and column chemistry is not comparable to one that does. Our specification: ≥99.0% main peak area by C18 RP-HPLC at 220 nm, confirmed by ESI-MS identity on every production lot.
The reference point
Novo Nordisk, founded in Denmark in 1923, developed and commercialized the first GLP-1 receptor agonist injectables at scale — liraglutide (Victoza, 2009) and semaglutide (Ozempic, 2017). These are synthetic peptides administered by subcutaneous injection. Their quality release standard — Ph. Eur.-compliant HPLC purity, endotoxin testing by LAL, mass spectrometry identity confirmation — is the global benchmark for injectable peptide analytical documentation. 'Danish Formulation Technology' names this tradition. Alpha Nordisk derives its analytical methodology from these same standards and applies them to every production lot we release.
Alpha Nordisk is not affiliated with Novo Nordisk A/S.
Observable methodology
Methodology is only meaningful when it is observable.
Every lot code issued by Alpha Nordisk corresponds to a Certificate of Analysis carrying the analytical data from the methods described above — HPLC chromatogram, ESI-MS confirmation, endotoxin result, water content, counterion identity. Enter a lot code to confirm.
Verify a lot →